Press Release regarding Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.

ANUPAM RASAYAN INDIA LTD. ARILSLDSTX20260814042 Date: August 14, 2026 To, T o , BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, ‘Exchange Plaza’, C-1, Block-G, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai-400001, India Mumbai-400051, India SCRIP CODE: 543275 SYMBOL: ANURAS Dear Sir/Madam, Subject: Intimation of Press Release. Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release to be issued by Anupam Rasayan India Limited (the “Company”) today i.e., August 14, 2026, regarding the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, approved by the Board of Directors of the Company. This Press Release will also be hosted on the website of the Company at www.anupamrasayan.com. We request you to kindly take note the same. Thanking you, Yours Faithfully, For Anupam Rasayan India Limited Anand Desai Managing Director DIN: 00038442 Encl.: As above Registered Office: Tel. : +91-261-2398991-95 Office Nos. 1101 to 1107, 11th Floor, Icon Rio, Fax : +91-261-2398996 Behind Icon Business Centre, Dumas Road, E-mail : office@anupamrasayan.com Surat-395007, Gujarat, India. Website : www.anupamrasayan.com CIN - L24231GJ2003PLC042988 Anupam Rasayan India Limited Q1 FY27 Earnings Press Release Surat, August 14th, 2026: Anupam Rasayan India Limited. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its unaudited financial results for the quarter ended June 30, 2026. Particulars (Rs. In Mn) Q1FY27 Q1FY26 YoY (%) FY26 Total Revenue 6,675 4,907 36% 23,836 EBITDA 1,749 1,292 35% 5,430 EBITDA Margin 26% 26% 23% PAT 512 485 6% 2,222 On Consolidated Basis Consolidated Financial Highlights for Quarter ended June 30th, 2026:  Total Revenue for Q1FY27 was Rs 6,675 Mn as compared to Rs 4,907 Mn in Q1FY26; up 36% YoY  EBITDA (incl. other income) came in at Rs 1,749 Mn in Q1FY27 as against Rs 1,292 Mn in Q1FY26; up 35% YoY, translating into EBITDA margin of 26.2% for Q1FY27.  Profit After Tax stood at Rs 512 Mn in Q1FY27 as compared to Rs 485 Mn in Q1FY26 Commenting on the performance, Mr. Anand Desai, Managing Director, Anupam Rasayan India Limited, said, "We are pleased to begin fiscal year 2027 on a strong note. Consolidated Revenue for the quarter grew 36% year-on-year, a result that reflects sustained momentum across our businesses and continued execution of our strategy to build a globally integrated specialty chemicals and CDMO platform. We would like to highlight an important technological milestone achieved during the quarter. We became the first company in the world to commercialize Ethyl Trifluoroacetate, or ETFA, using flow chemistry - a significant advancement that further strengthens our capabilities in complex fluorination. We also signed a Letter of Intent with BASQUEVOLT, S.A. for the potential long-term supply of a specialty chemical product. This represents a revenue opportunity of approximately US$300 million spread over a period of ten years. Turning to our pharmaceutical business, the proposed acquisition of Bliss GVS Pharma continues to progress as planned, following the signing of the definitive agreement. Upon completion, we expect this transaction to strengthen our pharmaceutical platform through synergies across CDMO capabilities, product development, customer relationships, and access to regulated markets. Looking ahead, we remain confident in our growth prospects. This confidence is supported by a strong product pipeline, expanding opportunities across our Performance Materials and Pharmaceuticals segments, deeper customer engagement, and continued investment in technology and innovation. Together, these initiatives position us well to deliver sustainable growth and long-term value creation." About Anupam Rasayan India Limited Anupam Rasayan India Limited (Anupam) is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India. Incorporated in 1984, the specialty chemicals major has two verticals: Life science related Specialty Chemicals comprising products related to Agrochemicals, Personal Care and Pharmaceuticals, Other Specialty Chemicals comprising Polymer Additives. Anupam caters to a diverse base of Indian and global customers. It is currently manufacturing products for over 200+ domestic and international customers. Anupam operates via its eight manufacturing facilities, with six facilities located in Gujarat, one in Tamil Nadu and one in U.S. with an aggregate installed capacity of ~2,00,000+ MT as of March 31, 2026. Anupam offers multistep synthesis and undertakes complex chemical reactions technologies, for a diverse base of Indian and global customers. For more information, please contact: Company Details Investor Relations Advisors Anupam Rasayan India Limited Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 CIN: L24231GJ2003PLC042988 Mr. Shrikant Sangani / Ms. Shaily Patwa www.anupamrasayan.com Email - shrikant.sangani@sgapl.net / shaily.p@sgapl.net Mobile No – 9619595686 / 9819494608 www.sgapl.net DISCLAIMER: Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Anupam Rasayan India Limited will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.